BiotechTube
InnoGI Technologies

InnoGI Technologies

Wageningen, Netherlands· Est.
innogitechnologies.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

InnoGI Technologies is a specialized CRO founded in 2016, offering predictive gastrointestinal modeling services via its TIM® Platform. The platform integrates dynamic in vitro models of the upper GI, colon, and intestinal epithelium with in silico PBPK modeling, creating a unique end-to-end simulation capability. It serves major pharmaceutical and food/nutrition companies, including engagements with regulatory bodies like the US FDA, to de-risk oral drug and nutritional product development. The company is positioned as a key enabler in the growing fields of microbiome modulation and sustainable oral formulation.

Gastroenterology

Technology Platform

The TIM® Platform: an integrated suite of dynamic in vitro GI models (Upper GI, Colon, Cell) and an in silico PBPK model (TIM PK) that simulates the entire human gastrointestinal tract for predicting digestion, bioavailability, ADME, and microbiome interactions.

Opportunities

The booming microbiome therapeutics and functional food markets create strong demand for predictive colon and digestion models.
The global shift towards alternative proteins and sustainable nutrition requires deep understanding of novel ingredient digestibility and impact, opening a significant new client vertical beyond traditional pharma.

Risk Factors

Revenue is tied to client R&D budgets, creating vulnerability to economic or sector downturns.
The company's reliance on a single, proprietary platform faces competition from emerging organ-on-a-chip and other dynamic model technologies.
Maintaining and expanding regulatory acceptance of its models is an ongoing requirement.

Competitive Landscape

InnoGI competes with other specialized CROs offering GI simulation services, as well as broader CROs with in-house dissolution and ADME capabilities. Its primary competitive advantage is the integration and physiological sophistication of the TIM® Platform, its long publication history, and regulatory endorsement. Key competitors may include companies like BioIVT (with GI services), simulated GI model providers, and academic core facilities.

More companies in Drug Delivery & Formulation →More companies in Netherlands →